latest news releases from the newsroom
Atlantis Business Development Corporation, Inc.
Atlantis Business Development Corporation Announces an Appointment to the Board of Directors
MIAMI, April 1, 2005 (PRIMEZONE) -- Atlantis Business Development Corporation, Inc. (OTCBB:ATBD) announced today that Dr. James P. Voloshin has been appointed to the Board of Directors. Dr. Voloshin is a practicing board certified Plastic Surgeon in Newport Beach, Ca. He has resided there since 1983. Besides being a member or past member of ten of the most significant plastic surgery medical societies, he has been active in many businesses and developments. In the late 70's and early 80's he was President of many building companies i.e. Center 80-81 Developments, Derby Ranches, Kingsway Professional Building, Kingsway Surgical Suite, among a few. He also was actively involved in building more than 600 apartment units. During this same period of time he was President of the Medical staff of a 1,000 bed city hospital, which was the seventh busiest hospital in North America at that time. He has held several other positions in community organizations. In more recent years he founded and later sold Surgical Funding Group, one of the early companies in medical financing. He has been actively involved in numerous other business ventures. Has been president of Newport Surgery Institute since 1996 and was on the board of MedPlus Corporation from 1996-2003. He has been on the board of directors of Central American Equities Inc., a public corporation, for the past 2 years.
Crucell's Cell-Culture Technology to Be Part of Major U.S. Government Influenza Pandemic Vaccine Program
LEIDEN, Netherlands, April 1, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that its partner sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract by the U.S. Department of Health and Human Services (HHS). The objective of the contract is to accelerate the licensure in the U.S. of a PER.C6(R) based cell-culture influenza vaccine and vaccine manufacturing facility. Crucell will be a subcontractor for the program. Terms of the subcontracting agreement between Crucell and sanofi pasteur were not disclosed.
TelePlus Enterprises, Inc.
TelePlus Announces Q4 and Full Year Results -- Sales Increased to $4.0M for the Quarter and $12.2M for the Full Year With Positive EBITDA
MONTREAL, April 1, 2005 (PRIMEZONE) -- TelePlus Enterprises, Inc. (OTCBB:TLPE) (http://www.teleplus.ca), a vertically integrated provider of wireless and landline communications products and services across North America, is pleased to announce its results for the 4th quarter and Full year ended December 31st, 2004. Sales for the 4th quarter increased by $1,239,508 (or 33%) to $3,996,467 as compared to $2,756,959 for the same period a year ago. The Company had a positive EBITDA of $7,228 and net loss of $40,407 (prior to financing costs, one-time non-recurring expenses and increase in other non-cash expenses) for the 4th quarter as compared to a positive EBITDA of $100,879 and a profit of $53,248 (before a one time tax recovery) for the same period a year ago. Average store sales were unchanged in the 4th quarter of 2004 versus the same period a year ago.
Heartland Holdings Inc. Announces Monumental Sales Increase
PLYMOUTH, Minn., April 1, 2005 (PRIMEZONE) -- Heartland Holdings Inc. (OTCBB:HTLJ) today announced a monumental sales increase for fiscal year 2004. In its most recent 10KSB filing with the Securities and Exchange Commission, the company reported a phenomenal, more than 1,000 percent sales increase, during fiscal year 2004 compared to fiscal year 2003.
ATSI Communications Inc.
ATSI Revenues Up 185 Percent
SAN ANTONIO, April 1, 2005 (PRIMEZONE) -- ATSI Communications, Inc. (OTCBB:ATSX) announced today that the Company expects revenues for the 3rd quarter ended April 30, 2005 to reach $1,600,000. In comparison, this is a 185% increase over the previous fiscal year's 3rd quarter ended April 30, 2004.
Telestone Technology Corp.
Telestone Technologies Fiscal 2004 Income Up 88 Percent
NEW YORK, April 1, 2005 (PRIMEZONE) -- Telestone Technologies Corporation (OTCBB:TESN) today announced that for the fiscal year ended December 31, 2004, it achieved net income, before extraordinary gain, of $4,144,000, or $1.14 per weighted average fully diluted share, representing an 88% increase in net income over 2003.